By Karen Roman Sequana Medical said the company now has five medical centers using its alfapump, the first FDA-approved active implantable medical device to treat liver ascites due to cirrhosis. The new implantations include the Dartmouth Hitchcock Medical Center and...

By Karen Roman SkylineDx said its Merlin CP-GEP molecular test is uniquely recognized by the National Comprehensive Cancer Network (NCCN) for predictive use in select T1 and T2 melanoma patients. The test provides informed risk stratification and helps physicians better understand...

By Karen Roman Now Optics, the parent company of Stanton Optical, said it is opening the first four “store-in-store” locations inside select Staples stores in the Philadelphia area. The stores will open in Wayne, Springfield, Bensalem and Willow Grove and...

By Exec Edge Editorial Staff Ascentage Pharma said China’s Center for Drug Evaluation has cleared its investigational new drug application for APG-3288, a next-generation Bruton’s tyrosine kinase (BTK) protein degrader, paving the way for clinical testing in the country and...

By Daniella Parra Iovance Biotherapeutics said Amtagvi had a 52% response rate with two or less prior therapies and 73% overall disease control rate when used earlier in the treatment for advanced melanoma. Amtagvi is a one-time T cell therapy...

By Karen Roman GlucoTrack, Inc. (Nasdaq: GCTK) said the U.S. Patent and Trademark Office issued three patents for its continuous blood glucose monitoring platform as the company moves toward commercializing it. The three patents protect key technologies related to proprietary...

By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said it is collaborating with medical device distributor Adriamed to deploy the Nanox.ARC, a digital tomosynthesis system, to healthcare providers across Serbia, Montenegro, and Bosnia and Herzegovina. Adriamed will be Nanox’s exclusive...

By Karen Roman Ascentage Pharma Group Internat (Nasdaq: AAPG) said its treatment candidate for B-cell diseases APG-3288 was granted the investigational new drug clearance by the FDA. The company will also conduct a global Phase I study evaluating APG-3288 in...

By Karen Roman Biopharmaceutical company Medera Inc. said it completed patient enrollment for Cohort B of its clinical trial evaluating SRD-002 gene therapy for heart failure with preserved ejection fraction (HFpEF). This milestone allows Medera to advance to Phase 2b...

By Karen Roman SkylineDx said it published new peer-reviewed data where its Merlin CP-GEP Test outperforms the competition and current standards of care for identifying melanoma risk using molecular testing. In response to a competitor’s study comparing its own test...